Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIGHT: ICG-enhanced qFME in Upper GI Tumours
NCT07108855Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indocyanine green in esophageal carcinoma and Gastric carcinoma (GC), sponsored by University Medical Center Groningen. Primary endpoint: Feasibility of ICG-enhanced qFME to determine tumour demarcation and depth in upper gastrointestinal tumours during ESD at 8 months. Started Sep 2025; status: recruiting.
02
Drugs
indocyanine green
03
Conditions
esophageal carcinomaGastric carcinoma (GC)
Beyond the preview
Go deeper on NCT07108855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108855.